Cargando…
Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes
Diabetes mellitus (DM) is a common disease worldwide. There is a strong association between DM and neurovascular and neurodegenerative disorders. The first group mainly consists of diabetic retinopathy, diabetic neuropathy and stroke, whereas, the second group includes Alzheimer’s disease, Parkinson...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564566/ https://www.ncbi.nlm.nih.gov/pubmed/32872672 http://dx.doi.org/10.3390/jcm9092807 |
_version_ | 1783595743914754048 |
---|---|
author | Gasecka, Aleksandra Siwik, Dominika Gajewska, Magdalena Jaguszewski, Miłosz J. Mazurek, Tomasz Filipiak, Krzysztof J. Postuła, Marek Eyileten, Ceren |
author_facet | Gasecka, Aleksandra Siwik, Dominika Gajewska, Magdalena Jaguszewski, Miłosz J. Mazurek, Tomasz Filipiak, Krzysztof J. Postuła, Marek Eyileten, Ceren |
author_sort | Gasecka, Aleksandra |
collection | PubMed |
description | Diabetes mellitus (DM) is a common disease worldwide. There is a strong association between DM and neurovascular and neurodegenerative disorders. The first group mainly consists of diabetic retinopathy, diabetic neuropathy and stroke, whereas, the second group includes Alzheimer’s disease, Parkinson’s disease, mild cognitive impairment and dementia. The aforementioned diseases have a common pathophysiological background including insulin resistance, oxidative stress, atherosclerosis and vascular injury. The increasing prevalence of neurovascular and neurodegenerative disorders among diabetic patients has resulted in an urgent need to develop biomarkers for their prediction and/or early detection. The aim of this review is to present the potential application of the most promising biomarkers of diabetes-related neurodegenerative and neurovascular disorders, including amylin, β-amyloid, C-reactive protein (CRP), dopamine, gamma-glutamyl transferase (GGT), glycogen synthase kinase 3β, homocysteine, microRNAs (mi-RNAs), paraoxonase 1, phosphoinositide 3-kinases, tau protein and various growth factors. The most clinically promising biomarkers of neurovascular and neurodegenerative complications in DM are hsCRP, GGT, homocysteine and miRNAs. However, all biomarkers discussed in this review could become a part of the potential multi-biomarker screening panel for diabetic patients at risk of neurovascular and neurodegenerative complications. |
format | Online Article Text |
id | pubmed-7564566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75645662020-10-29 Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes Gasecka, Aleksandra Siwik, Dominika Gajewska, Magdalena Jaguszewski, Miłosz J. Mazurek, Tomasz Filipiak, Krzysztof J. Postuła, Marek Eyileten, Ceren J Clin Med Review Diabetes mellitus (DM) is a common disease worldwide. There is a strong association between DM and neurovascular and neurodegenerative disorders. The first group mainly consists of diabetic retinopathy, diabetic neuropathy and stroke, whereas, the second group includes Alzheimer’s disease, Parkinson’s disease, mild cognitive impairment and dementia. The aforementioned diseases have a common pathophysiological background including insulin resistance, oxidative stress, atherosclerosis and vascular injury. The increasing prevalence of neurovascular and neurodegenerative disorders among diabetic patients has resulted in an urgent need to develop biomarkers for their prediction and/or early detection. The aim of this review is to present the potential application of the most promising biomarkers of diabetes-related neurodegenerative and neurovascular disorders, including amylin, β-amyloid, C-reactive protein (CRP), dopamine, gamma-glutamyl transferase (GGT), glycogen synthase kinase 3β, homocysteine, microRNAs (mi-RNAs), paraoxonase 1, phosphoinositide 3-kinases, tau protein and various growth factors. The most clinically promising biomarkers of neurovascular and neurodegenerative complications in DM are hsCRP, GGT, homocysteine and miRNAs. However, all biomarkers discussed in this review could become a part of the potential multi-biomarker screening panel for diabetic patients at risk of neurovascular and neurodegenerative complications. MDPI 2020-08-30 /pmc/articles/PMC7564566/ /pubmed/32872672 http://dx.doi.org/10.3390/jcm9092807 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gasecka, Aleksandra Siwik, Dominika Gajewska, Magdalena Jaguszewski, Miłosz J. Mazurek, Tomasz Filipiak, Krzysztof J. Postuła, Marek Eyileten, Ceren Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes |
title | Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes |
title_full | Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes |
title_fullStr | Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes |
title_full_unstemmed | Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes |
title_short | Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes |
title_sort | early biomarkers of neurodegenerative and neurovascular disorders in diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564566/ https://www.ncbi.nlm.nih.gov/pubmed/32872672 http://dx.doi.org/10.3390/jcm9092807 |
work_keys_str_mv | AT gaseckaaleksandra earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT siwikdominika earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT gajewskamagdalena earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT jaguszewskimiłoszj earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT mazurektomasz earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT filipiakkrzysztofj earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT postułamarek earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes AT eyiletenceren earlybiomarkersofneurodegenerativeandneurovasculardisordersindiabetes |